Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

The Therapeutic Effects of Ceylon Cinnamon Supplementation and a Self-Efficacy Educational Program on Glycemic Control, Lipid Profiles, and Pain in Type 2 Diabetes Mellitus With Painful Diabetic Peripheral Neuropathy (Ceylon-EDU-RCT)

7. August 2026 aktualisiert von: JAWAD AHMAD ABU-SHENNAR, Jerash Private University

The Therapeutic Effects of Ceylon Cinnamon Supplementation and a Self-Efficacy Educational Program on Glycemic Control, Lipid Profiles, and Pain in Type 2 Diabetes Mellitus With Painful Diabetic Peripheral Neuropathy: A Randomized Controlled Trial

This randomized controlled trial aims to evaluate the therapeutic effects of pure Ceylon cinnamon (Cinnamomum verum) supplementation combined with a structured self-efficacy-based educational program on glycemic control, lipid profiles, and neuropathic pain in adult patients with type 2 diabetes mellitus (T2DM) and painful diabetic peripheral neuropathy (PDPN). A total of 900 participants will be randomly assigned to three parallel arms: a standard care control group, a Ceylon cinnamon supplementation group (1,000 mg/day), and a combined intervention group (Ceylon cinnamon supplementation plus the self-efficacy educational program) over a 6-month period. The study hypothesizes that the combined approach will significantly improve glycemic parameters, reduce neuropathic pain severity, and enhance metabolic profiles compared to standard care alone.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Type 2 diabetes mellitus (T2DM) is a major global health challenge often complicated by diabetic peripheral neuropathy (DPN), which frequently manifests as painful diabetic peripheral neuropathy (PDPN) and severely compromises patients' quality of life. Conventional pharmacological treatments for PDPN often produce limited efficacy and adverse side effects, necessitating safe and effective complementary interventions.

This study is a prospective, three-group, parallel-arm, randomized controlled trial (RCT) designed to investigate the synergistic therapeutic impact of botanical supplementation and behavioral education. A total of 900 eligible adult participants diagnosed with T2DM and PDPN attending clinical healthcare centers will be enrolled and randomly allocated in a 1:1:1 ratio into one of three trial arms:

Control Group (Standard Care, n = 300): Participants receive routine diabetic medical care, standard counseling, and matching placebo capsules administered twice daily for 6 months, without structured educational interventions.

Cinnamon Supplementation Group (n = 300): Participants receive standard routine care alongside pure Ceylon cinnamon (Cinnamomum verum) extract capsules (500 mg orally twice daily with meals, total daily dose: 1,000 mg) for 6 months, combined with a double-blind placebo control for the educational component.

Combined Intervention Group (n = 300): Participants receive the identical daily regimen of 1,000 mg Ceylon cinnamon supplementation for 6 months, integrated with a structured, theory-driven Self-Efficacy-Based Educational Program grounded in Bandura's social cognitive theory. The educational program focuses on self-monitoring of blood glucose (SMBG), medication and supplement adherence, dietary modifications, foot care, and psychological coping strategies for chronic pain.

Primary and Secondary Endpoints:

Evaluations will be conducted at baseline and 6 months post-intervention. Primary outcomes include changes in glycated hemoglobin (HbA1c), fasting blood glucose (FBG), insulin resistance (HOMA-IR), and neuropathic pain severity assessed via the Numeric Rating Scale (NRS). Secondary outcomes include lipid profile biomarkers (Total Cholesterol, Triglycerides, LDL-C, and HDL-C), patient adherence, and safety/adverse event tracking. Statistical analyses will utilize repeated measures ANOVA and mixed-model frameworks to evaluate longitudinal and between-group differences.

Studientyp

Interventionell

Einschreibung (Geschätzt)

900

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Dr. Jawad AHMAD ABU-SHENNAR, Asst.Prof.Dr
  • Telefonnummer: +962779084560
  • E-Mail: JAWAD_0799@YAHOO.COM

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  • Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 6 months.
  • Confirmed diagnosis of painful diabetic peripheral neuropathy (PDPN).
  • Age between 18 and 65 years.
  • Able to provide written informed consent and willing to comply with the study protocol, supplement intake, and educational sessions.

Exclusion Criteria:

  • Type 1 diabetes mellitus or gestational diabetes.
  • Severe renal or hepatic impairment.
  • Known allergy, hypersensitivity, or contraindication to cinnamon or related botanical products.
  • Pregnancy or lactation.
  • Concurrent participation in another clinical trial or severe psychiatric/cognitive disorders that hinder study participation.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Matching Placebo Group
Participants receive routine diabetes medical care and matching placebo capsules administered twice daily for 6 months.
Placebo capsules identical in appearance, color, and packaging to the cinnamon supplement, taken twice daily for 6 months
Experimental: Ceylon Cinnamon Group
Participants receive routine diabetes medical care and pure Ceylon cinnamon (Cinnamomum verum) extract capsules (500 mg orally twice daily, total daily dose: 1,000 mg) for 6 months.
Placebo capsules identical in appearance, color, and packaging to the cinnamon supplement, taken twice daily for 6 months
Pure Ceylon cinnamon extract capsules (500 mg per capsule, taken twice daily, total dose 1,000 mg/day for 6 months).
Experimental: Combined Intervention Group
Participants receive routine diabetes medical care, 1,000 mg/day Ceylon cinnamon supplementation for 6 months, and a structured Self-Efficacy-Based Educational Program grounded in Bandura's social cognitive theory.
Pure Ceylon cinnamon extract capsules (500 mg per capsule, taken twice daily, total dose 1,000 mg/day for 6 months).
A structured educational program grounded in Bandura's social cognitive theory aimed at enhancing self-efficacy and self-management skills evaluated using the Diabetes Self-Efficacy Scale (DSES)in participants with diabetes

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Glycated Hemoglobin (HbA1c)
Zeitfenster: Baseline and 6 months
Evaluated from venous blood samples to assess glycemic control over the preceding 2 to 3 months, expressed as a percentage (%). Lower values indicate a better outcome (improved long-term glycemic control). Normal reference ranges typically fall below 5.7%, with diabetes management targets generally aiming for levels below 7.0%
Baseline and 6 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Fasting Blood Glucose (FBG)
Zeitfenster: Baseline, 3 months, and 6 months
Description: Evaluated from venous blood samples collected following an 8-hour overnight fast, measured in milligrams per deciliter (mg/dL). Lower values indicate a better outcome (improved fasting glycemic status).
Baseline, 3 months, and 6 months
Change in Lipid Profile Parameters
Zeitfenster: Baseline and 6 months

Evaluated from venous blood samples collected following an 8-hour overnight fast, measured in milligrams per deciliter (mg/dL). Directionality of improvement varies by component:

Total Cholesterol: Lower values indicate a better outcome.

Triglycerides: Lower values indicate a better outcome.

Low-Density Lipoprotein Cholesterol (LDL-C): Lower values indicate a better outcome.

High-Density Lipoprotein Cholesterol (HDL-C): Higher values indicate a better outcome.

Baseline and 6 months
Change in Neuropathic Pain Intensity
Zeitfenster: Baseline and 6 months (or Baseline, 3 months, and 6 months according to your protocol)
Evaluated using the Numerical Rating Scale (NRS). Participants rate their average neuropathic pain intensity over the preceding 7 days. Scores range from a minimum value of 0 (no pain) to a maximum value of 10 (worst possible pain). Higher scores indicate a worse outcome (greater pain intensity). Pain severity is categorized as mild (1-3), moderate (4-7), or severe (8-10).
Baseline and 6 months (or Baseline, 3 months, and 6 months according to your protocol)
Change in Diabetes Self-Efficacy Score
Zeitfenster: Baseline and 6 months
Evaluated using the Diabetes Self-Efficacy Scale (DSES). Item scores range from a minimum value of 1 (not at all confident) to a maximum value of 10 (totally confident), reported as an overall mean score (range 1-10). Higher scores indicate
Baseline and 6 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. August 2026

Primärer Abschluss (Geschätzt)

1. Dezember 2026

Studienabschluss (Geschätzt)

1. Dezember 2026

Studienanmeldedaten

Zuerst eingereicht

31. Juli 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

7. August 2026

Zuerst gepostet (Tatsächlich)

11. August 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

11. August 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

7. August 2026

Zuletzt verifiziert

1. Juli 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • Educat vs. Ceyl-2026

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .